Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Curis, Inc.

Immunome is a clinical-stage targeted oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company has an innovative portfolio of therapeutics, including antibody-drug conjugates and treatments for desmoid tumors.

Immunome

Curis, Inc is focused on developing innovative therapeutics for the treatment of cancer, specifically targeting hematologic malignancies and other cancers. This includes their marketed product, Erivedge, and several drugs in their pipeline.

Metric
Company Name	Curis, Inc.	Immunome
Symbol	CRIS
MSH ID	COM:CURIS	COM:IMMUNOME
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	US
Stage
Employee Count	49
Website	curis.com	immunome.com
LinkedIn		immunome-inc-
Founders

Metric
Market Cap	40.49M
Enterprise Value
Monthly Web Traffic	1.77K
Web Traffic Growth	-0.41
Valuation
Raised Capital

Metric
Revenue	10.02M
Revenue (LTM)
Revenue (NTM)
Gross Profit	10.02M
EBITDA	-48.33M
Operating Income	-48.33M
Net Income	-47.41M
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.97
Operating Profit Margin	-4.82
EBITDA Margin	-4.82
Net Profit Margin	-4.69
Return on Equity	-1.69
Return on Assets	-0.61
Return on Capital Employed	-0.76

COM:CURIS

Curis, Inc

Last Close

4.10

22/11 21:00

Market Cap

40.49M

Beta: -

Volume Today

107.98K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.01
P/B Ratio	1.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.92
EV Multiple	0.14

Metric
Days Sales Outstanding	101.77
Days Payables Outstanding	8.32K
Days Inventory Outstanding
Operating Cycle	101.75
Cash Conversion Cycle	-1.09K
Asset Turnover	0.20

Metric
Operating Cash Flow	-38.43M
Free Cash Flow	-38.43M
Cash Flow to Debt	-0.95
Operating Cash Flow/Sales	-3.83
Free Cash Flow Yield	-0.61

Metric
Cash & Equivalents	26.68M
Accounts Receivable	181K
Inventory
Goodwill	8.98M
Debt to Capitalization	1.02
Debt to Assets	0.05
Current Ratio	6.19
Quick Ratio	4.37

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.61
R&D to Revenue	3.74
SG&A to Revenue	1.77